Institution profile

医療法人Fuvenant 青木優美クリニック

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 02G2601009 +3

Location

Prefecture
Fukuoka
Address
福岡市博多区博多駅東2-5-33ゲートスクエア博多駅前3F

Plan classification

  • Class INot registered
  • Class IINot registered
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • 患者の集いモミの木再生医療等委員会
  • 日本薬事法務学会再生医療等委員会

Public score

32.1/ 100

A · Review level
10.0 / 30
B · Technologies
18.5 / 35
C · Coverage
3.6 / 25
D · Class I / II technologies
0.0 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Overall ranking

No. 1506of 1736

Registered technologies
4
Areas covered
1

Technology areas · Rank

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 32.1
Public score →100

Registered technologies (4)

NK and immune cells 4
Registered technologies · Japanese originalTechnology areasPlan classification
全血採血によるGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®Ⅱ)NK and immune cellsClass III
悪性腫瘍に対する自己活性化 NK 細胞療法(NK細胞療法)NK and immune cellsClass III
悪性腫瘍に対する自家培養樹状細胞を用いた樹状細胞ワクチン療法(樹状細胞(DC)ワクチン療法)NK and immune cellsClass III
成分採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)NK and immune cellsClass III

Certified committee for regenerative medicine

  • 患者の集いモミの木再生医療等委員会
  • 日本薬事法務学会再生医療等委員会

Public document number

  • 02G2601009
  • 02G2601010
  • 02G2601004
  • 02G2601005
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
悪性腫瘍に対する自己活性化 NK 細胞療法(NK細胞療法)Class III患者の集いモミの木再生医療等委員会02G2601009
悪性腫瘍に対する自家培養樹状細胞を用いた樹状細胞ワクチン療法(樹状細胞(DC)ワクチン療法)Class III患者の集いモミの木再生医療等委員会02G2601010
成分採血での悪性腫瘍の抑制及び治療のためのGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®)Class III日本薬事法務学会再生医療等委員会02G2601004
全血採血によるGMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®Ⅱ)Class III日本薬事法務学会再生医療等委員会02G2601005

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor